Published in Nat Med on June 01, 2012
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature (2015) 5.15
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell (2014) 4.53
Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov (2013) 4.35
Tumour exosome integrins determine organotropic metastasis. Nature (2015) 4.09
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol (2015) 4.08
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature (2015) 3.83
The perivascular niche regulates breast tumour dormancy. Nat Cell Biol (2013) 3.36
Regulation of immune responses by extracellular vesicles. Nat Rev Immunol (2014) 3.24
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol (2012) 3.18
Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles (2015) 3.02
Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell (2014) 2.90
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun (2013) 2.66
Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol (2013) 2.61
Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell (2014) 2.41
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature (2016) 2.33
Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A (2013) 2.32
Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics (2013) 2.27
Immune cell promotion of metastasis. Nat Rev Immunol (2015) 2.15
Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol (2014) 2.15
Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) (2013) 2.12
Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature (2016) 2.11
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res (2014) 2.00
Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem (2014) 1.92
Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. J Biol Chem (2013) 1.84
Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci (2013) 1.81
Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol (2013) 1.73
Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood (2015) 1.70
In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell (2015) 1.65
Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem (2013) 1.62
How pure are your vesicles? J Extracell Vesicles (2013) 1.62
Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics (2012) 1.55
Sorting it out: regulation of exosome loading. Semin Cancer Biol (2014) 1.54
Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol (2013) 1.54
Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival. Nat Cell Biol (2015) 1.51
Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci (2013) 1.50
Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem (2013) 1.49
MSC Transplantation Improves Osteopenia via Epigenetic Regulation of Notch Signaling in Lupus. Cell Metab (2015) 1.49
Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia (2013) 1.49
Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol (2016) 1.49
Selection and adaptation during metastatic cancer progression. Nature (2013) 1.46
Mechanisms of lymphatic metastasis. J Clin Invest (2014) 1.46
Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol (2012) 1.45
Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids. Mol Cell Proteomics (2012) 1.44
Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol (2015) 1.44
Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance. J Transl Med (2013) 1.43
Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans (2013) 1.42
The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles. J Extracell Vesicles (2014) 1.40
A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol (2014) 1.40
Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes. PLoS One (2016) 1.40
Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol (2015) 1.37
Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem (2013) 1.37
Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun (2015) 1.37
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer (2013) 1.36
Extracellular vesicles: emerging targets for cancer therapy. Trends Mol Med (2014) 1.35
S100 proteins in cancer. Nat Rev Cancer (2015) 1.35
Metastatic colonization by circulating tumour cells. Nature (2016) 1.31
Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol Toxicol (2014) 1.29
Exosomes in cancer: small particle, big player. J Hematol Oncol (2015) 1.29
Differential fates of biomolecules delivered to target cells via extracellular vesicles. Proc Natl Acad Sci U S A (2015) 1.27
Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano (2014) 1.26
Targeting metastasis. Nat Rev Cancer (2016) 1.26
Exosome secretion is enhanced by invadopodia and drives invasive behavior. Cell Rep (2013) 1.26
Transfer of extracellular vesicles during immune cell-cell interactions. Immunol Rev (2013) 1.25
The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta (2015) 1.25
Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget (2014) 1.25
The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J (2013) 1.24
FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver. Pharmaceuticals (Basel) (2013) 1.24
Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Semin Cell Dev Biol (2015) 1.23
Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem (2013) 1.22
Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun (2014) 1.21
Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol (2012) 1.21
Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget (2015) 1.21
The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids. Front Genet (2013) 1.21
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci U S A (2014) 1.21
Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells (2014) 1.20
Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherin. Nat Commun (2013) 1.20
Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res (2013) 1.19
Functions and therapeutic roles of exosomes in cancer. Front Oncol (2014) 1.18
Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ (2014) 1.18
Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci U S A (2015) 1.17
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Hypoxic control of metastasis. Science (2016) 1.16
Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene (2014) 1.14
Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma. J Extracell Vesicles (2015) 1.14
microRNA-mediated regulation of the tumor microenvironment. Cell Cycle (2013) 1.14
Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia (2013) 1.14
Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix Biol (2015) 1.14
Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res (2015) 1.14
Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. Prostate (2014) 1.14
Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun (2015) 1.13
New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med (2015) 1.12
Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12
Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle (2013) 1.12
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 37.10
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 19.86
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol (2009) 13.01
Shedding microvesicles: artefacts no more. Trends Cell Biol (2009) 8.84
Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol (2008) 7.30
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia (2006) 6.45
Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 6.31
Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol (2006) 5.82
Exosomes: a common pathway for a specialized function. J Biochem (2006) 5.79
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol (2009) 5.44
The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 5.28
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer (2011) 4.54
An integrated approach to uncover drivers of cancer. Cell (2010) 4.53
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun (2011) 4.07
Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res (2011) 3.73
Targeting the c-Met signaling pathway in cancer. Clin Cancer Res (2006) 3.57
Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer (2006) 3.45
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol (2008) 3.30
Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ (2007) 3.22
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One (2009) 3.10
The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol (2011) 2.83
Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer (2009) 2.64
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res (2010) 2.62
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20
Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst (1976) 2.09
Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res (2010) 2.02
Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Exp Hematol (2010) 2.01
Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res (2009) 1.99
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. Stem Cells (2007) 1.92
Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochem Pharmacol (2009) 1.85
CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia (2009) 1.80
Examining the metastatic niche: targeting the microenvironment. Semin Oncol (2010) 1.71
Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst (2010) 1.65
Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. Mol Cancer Res (2008) 1.64
Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol (2010) 1.61
Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett (2009) 1.60
Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta (2009) 1.54
Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. Breast Dis (2007) 1.47
Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood (2010) 1.44
Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes. Exp Oncol (2006) 1.31
Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol (2010) 1.23
Characterization of plasma membrane shedding from murine melanoma cells. Int J Cancer (1988) 1.15
The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem (2001) 1.13
Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drugs (2010) 1.09
Critical determinants of melanoma metastasis. J Investig Dermatol Symp Proc (1996) 1.01
The HGF/c-Met axis synergizes with G-CSF in the mobilization of hematopoietic stem/progenitor cells. Stem Cells Dev (2010) 1.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem (2008) 10.08
Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell (2002) 9.36
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med (2003) 7.14
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res (2008) 6.95
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. Nature (2005) 6.40
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science (2013) 6.29
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell (2012) 5.53
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 5.28
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer (2002) 5.02
Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature (2010) 4.78
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med (2003) 4.69
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene (2002) 4.20
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun (2011) 4.07
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol (2004) 4.06
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles (2013) 4.05
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med (2002) 4.00
E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell (2002) 3.87
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res (2007) 3.63
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst (2007) 3.60
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest (2012) 3.45
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
The perivascular niche regulates breast tumour dormancy. Nat Cell Biol (2013) 3.36
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell (2011) 3.32
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell (2008) 3.09
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Expression patterns and post-translational modifications associated with mammalian histone H3 variants. J Biol Chem (2005) 3.00
SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature (2012) 2.96
Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev (2008) 2.95
Preparing the "soil": the premetastatic niche. Cancer Res (2006) 2.92
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res (2010) 2.88
The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol (2011) 2.83
AC133/CD133/Prominin-1. Int J Biochem Cell Biol (2005) 2.80
SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res (2007) 2.80
Asymmetrically modified nucleosomes. Cell (2012) 2.79
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Physiology of the prion protein. Physiol Rev (2008) 2.65
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev (2009) 2.59
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell (2008) 2.57
The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol (2009) 2.56
Expansion and maintenance of human embryonic stem cell-derived endothelial cells by TGFbeta inhibition is Id1 dependent. Nat Biotechnol (2010) 2.54
High throughput characterization of combinatorial histone codes. Mol Cell Proteomics (2009) 2.52
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature (2010) 2.49
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol (2012) 2.46
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
In vivo residue-specific histone methylation dynamics. J Biol Chem (2009) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med (2003) 2.30
The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29